Total Payments
$763,964
2024 Payments
$146,159
Companies
27
Transactions
1,273
Medicare Patients
3,865
Medicare Billing
$293,531
Payment Breakdown by Category
Other$611,616 (80.1%)
Travel$72,223 (9.5%)
Consulting$44,198 (5.8%)
Food & Beverage$31,198 (4.1%)
Education$4,729 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $579,898 | 321 | 75.9% |
| Travel and Lodging | $72,223 | 307 | 9.5% |
| Consulting Fee | $44,198 | 20 | 5.8% |
| Food and Beverage | $31,198 | 455 | 4.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,578 | 12 | 2.8% |
| Honoraria | $8,940 | 4 | 1.2% |
| Education | $4,729 | 153 | 0.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,200 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $308,040 | 487 | $0 (2024) |
| Lilly USA, LLC | $131,971 | 212 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $74,668 | 126 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $57,413 | 109 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $37,930 | 33 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $37,665 | 46 | $0 (2024) |
| Abbott Laboratories | $30,830 | 51 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $27,713 | 64 | $0 (2023) |
| Dexcom, Inc. | $19,089 | 53 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $10,298 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146,159 | 251 | Lilly USA, LLC ($48,018) |
| 2023 | $83,780 | 126 | Lilly USA, LLC ($21,238) |
| 2022 | $123,583 | 214 | Lilly USA, LLC ($51,713) |
| 2021 | $56,971 | 102 | Novo Nordisk Inc ($33,444) |
| 2020 | $40,061 | 62 | Novo Nordisk Inc ($21,216) |
| 2019 | $90,453 | 145 | Novo Nordisk Inc ($64,740) |
| 2018 | $87,955 | 146 | Novo Nordisk Inc ($46,711) |
| 2017 | $135,003 | 227 | Novo Nordisk Inc ($58,690) |
All Payment Transactions
1,273 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: DIABETES | ||||||
| 12/12/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $6.09 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | VIVUS LLC | QSYMIA (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: Diabetes Care | ||||||
| 12/09/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 12/09/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Diabetes | ||||||
| 12/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $87.70 | General |
| Category: Cardio-renal | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Honoraria | Cash or cash equivalent | $2,940.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,937.50 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $5.29 | General |
| Category: DIABETES | ||||||
| 12/04/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $9.06 | General |
| Category: Endocrinology | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,834.00 | General |
| Category: Cardio-renal | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $142.07 | General |
| Category: Cardio-renal | ||||||
| 11/14/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $4.88 | General |
| Category: Endocrinology | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,915.00 | General |
| Category: Endocrinology | ||||||
| 11/05/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,298.00 | General |
| Category: Endocrinology | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $207.28 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $156.96 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $132.42 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $65.47 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $65.47 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $49.10 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,046 | 2,441 | $361,657 | $94,382 |
| 2022 | 15 | 1,039 | 1,417 | $298,284 | $74,913 |
| 2021 | 12 | 879 | 1,208 | $262,877 | $65,435 |
| 2020 | 15 | 901 | 1,058 | $228,791 | $58,800 |
Total Patients
3,865
Total Services
6,124
Medicare Billing
$293,531
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 317 | 434 | $140,182 | $42,164 | 30.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 1,020 | $59,160 | $19,095 | 32.3% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 157 | 306 | $60,894 | $8,259 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 84 | $18,396 | $5,729 | 31.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 30 | $13,020 | $4,544 | 34.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $15,625 | $4,535 | 29.0% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 24 | 27 | $14,904 | $3,121 | 20.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 176 | 240 | $16,560 | $2,285 | 13.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 23 | $4,991 | $1,532 | 30.7% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 31 | 33 | $9,768 | $1,400 | 14.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 15 | $1,785 | $590.10 | 33.1% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 116 | 142 | $3,976 | $546.70 | 13.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 36 | 45 | $900.00 | $378.00 | 42.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 17 | $1,496 | $202.98 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 294 | 373 | $120,479 | $36,737 | 30.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 132 | 256 | $50,944 | $7,113 | 14.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $25,000 | $6,518 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 41 | 74 | $16,274 | $4,581 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 59 | 60 | $13,140 | $4,145 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 24 | $10,416 | $3,425 | 32.9% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 173 | 244 | $16,836 | $2,330 | 13.8% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 14 | 18 | $9,936 | $2,328 | 23.4% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2022 | 38 | 42 | $12,432 | $2,153 | 17.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 26 | 44 | $5,632 | $1,457 | 25.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 12 | $3,000 | $1,174 | 39.1% |
About Dr. Anthony Pick, M.D
Dr. Anthony Pick, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Deerfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942373527.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Pick, M.D has received a total of $763,964 in payments from pharmaceutical and medical device companies, with $146,159 received in 2024. These payments were reported across 1,273 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($579,898).
As a Medicare-enrolled provider, Pick has provided services to 3,865 Medicare beneficiaries, totaling 6,124 services with total Medicare billing of $293,531. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Deerfield, IL
- Active Since 11/15/2006
- Last Updated 12/19/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1942373527
Products in Payments
- Saxenda (Drug) $98,400
- JARDIANCE (Drug) $75,592
- INVOKANA (Drug) $74,619
- MOUNJARO (Drug) $61,884
- Ozempic (Drug) $49,576
- Kerendia (Drug) $37,930
- ZEPBOUND (Drug) $31,023
- TZIELD (Biological) $30,325
- RYBELSUS (Drug) $28,830
- FARXIGA (Drug) $27,562
- FREESTYLE LIBRE 3 (Device) $23,525
- Wegovy (Drug) $22,958
- Victoza (Drug) $20,299
- Tresiba (Drug) $19,175
- DEXCOM G7 GSS (161) (Medical Supply) $18,498
- Rybelsus (Drug) $17,746
- Livalo (Drug) $9,162
- REZDIFFRA (Drug) $6,645
- GVOKE HYPOPEN (Drug) $6,439
- EVERSENSE E3 SENSOR KIT - RETAIL (Device) $4,139
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.